此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

个人和家庭的罕见肿瘤和癌症易感性

2026年11月2日 更新者:National Cancer Institute (NCI)

Background:

Some people may be prone to develop cancer for many reasons. Factors that affect their risk include the genes they inherit and the environment they live and work in. Researchers want to learn more about the natural history of cancer.

Objective:

To understand how genes and environmental factors can cause tumors and related conditions.

Eligibility:

People of any age who:

Have tumors of an unusual type, pattern, or number

Have a family member with a history of cancer

Have been exposed to other factors that may increase their risk of cancer

Design:

This study does not involve treatment.

Participants will answer questions about their personal and family medical history. They will give permission for researchers to see their medical records.

Participants may be invited to the NIH Clinical Center for a physical exam. They may give samples including saliva, cheek cells, blood, urine, skin, and/or hair.

Participants with cancer may give bone marrow. A needle will be used to remove a small sample of bone marrow from their hip bone.

Participants may have a biopsy of their tumor.

Participants may have other exams:

Dental

Ear, nose, and throat

Eye

Hearing

Heart function and structure

Participants with cancer may undergo more exams:

A test of how much energy their body uses when resting

A sleep study with a test that measures brain electrical activity. They will have sensors attached to their body while they sleep overnight in a lab.

Imaging scans, such as CT, MRI, a test to measure how dense their bones are (DEXA), and ultrasound.

Participants will have their genes tested. A counsellor will help them understand the results.

Participants will be followed until at least 2035.

研究概览

详细说明

Study Description: The overall purpose of this study is to comprehensively and longitudinally evaluate the natural history of participants with rare tumors, genetic syndromes, genetic variants, and/or family history consistent with or hypothesized to contribute to predisposition to cancer(s) of interest to DCEG investigators. It will also facilitate evaluation of patients who may be candidates for other NIH Clinical Center (CC) clinical trials. These individuals and families will be evaluated and followed longitudinally to define the clinical spectrum (e.g., disease course, cancer risks, response to therapies, survival) and other phenotypic manifestations associated with rare tumors, genetic variants, and cancer predisposition syndromes.

Objectives:

  1. To evaluate and define the clinical spectrum (phenotype), penetrance and natural history of disease in syndromes predisposing to cancer;
  2. To evaluate the phenotypes and natural history arising from known -or suspected- pathogenic germline variants in known -or suspected cancer-susceptibility genes;
  3. To evaluate potential neoplastic precursor conditions in individuals and families at risk of cancer;
  4. To quantify site-specific risks of such tumors in family members;
  5. To discover, map, and determine inheritance patterns and functions of cancer susceptibility genes;
  6. To identify etiologically or clinically relevant changes to the somatic genome in these patients;
  7. To educate and counsel study participants about cancer risk including quantitative risk assessment and communication; prevention and surveillance recommendations; early detection activities; and management recommendations, when known.
  8. To facilitate and enhance enrollment in interventional clinical trials within the NCI or other Institutes.

Endpoints:

Primary Endpoint: The general goals of the research conducted under this protocol are to:

  1. Discover germline cancer susceptibility genes
  2. Define the natural history and clinical spectrum of disease in high risk cancer susceptibility families
  3. Define potential precursor states
  4. Quantify risks of cancers in family members
  5. Identify differences between familial and sporadic neoplasia
  6. Identify genetic determinants, environmental risk factors, gene-environment, and gene-gene interactions in high risk families
  7. Characterize the somatic genome of tumors from participants.

Secondary Endpoints:

  1. Define penetrance of tumors in family members
  2. Create full protocols for specific tumors or syndromes based on the pilot studies conducing within this study

研究类型

观察性的

注册 (估计的)

500

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Maryland
      • Bethesda、Maryland、美国、20892
        • 招聘中
        • National Institutes of Health Clinical Center
      • Rockville、Maryland、美国、20850
        • 招聘中
        • NIH National Cancer Institute - Shady Grove

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1年 至 99年 (孩子、成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

primary clinical; volunteers come from all across the U.S.

描述

  • INCLUSION CRITERIA:

Although specific familial syndromes vary in prevalence by sex, race or ethnicity, no one is excluded from participation by sex, gender, race or ethnicity. Since families participate in studies, the sex distribution is essentially balanced, and all ages are included. Minor children below the age of assent are actively studied only when the benefits of participation outweigh the risks.

Affected: An individual who meets any of the following criteria will be eligible to participate in this study:

  1. Personal medical history of neoplasia of an unusual type, pattern, or number; or,

  2. Known or suspected factor(s) predisposing to neoplasia, either genetic and/or congenital factors (birth defects, metabolic phenotype, chromosomal anomalies or Mendelian traits associated with tumors), environmental exposure (medications, occupation, radiation,

    diet, infectious agents, etc.), or unusual demographic features (very young age of onset, multiple tumors, etc.).

  3. There is no age restriction; therefore including viable neonates However, children < 3 years old will not come to the Clinical Center unless clinically indicated until they are >= 3 years old.

  4. Participant or their Legally Authorized Representative (LAR) must sign and date an IRB approved informed consent form (signed on paper or electronically for the Field Cohort / signed on paper for the Clinic Center Cohort)

Unaffected Controls: An individual who meets any of the following criteria will be eligible to participate in this study:

  1. Family medical history of neoplasia of an unusual type, pattern, or number; or,

  2. Known or suspected factor(s) predisposing to neoplasia, either genetic and/or congenital factors (birth defects, metabolic phenotype, chromosomal anomalies or Mendelian traits associated with tumors), environmental exposure (medications, occupation, radiation,

    diet, infectious agents, etc.), or unusual demographic features (very young age of onset, multiple tumors, etc.).

  3. There is no age restriction; therefore including viable neonates. However, children < 3 years old will not come to the Clinical Center unless clinically indicated until they are >= 3 years old.

  4. Participant or their LAR must sign and date an IRB-approved informed consent form (signed on paper or electronically for the Field Cohort / signed on paper for the Clinic Center Cohort)

Personal and family medical history will be verified through questionnaires, interviews, and review of pathology slides and medical records. For familial neoplasms, two or more living affected cases among family members are required. The types of suspected factors predisposing to neoplasia and/or familial tumors under active accrual and study will be investigator- and hypothesis-driven. This approach permits CGB investigators to remain alert to the opportunities afforded by clusters of rare tumors in families and individuals, and to be more responsive to the dynamic research priorities in cancer genetics.

EXCLUSION CRITERIA:

Affected: An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Referred individuals for whom reported diagnoses cannot be verified
  2. Inability of the participant or LAR to understand and be willing to sign a written informed consent document.
  3. Referred individuals who are eligible for other CGB protocols that are specific to a hereditary cancer syndrome (e.g., Li-Fraumeni Syndrome, Familial Melanoma) Unaffected Controls: An individual who meets any of the following criteria will be excluded

from participation in this study:

  1. Referred families for whom reported diagnoses cannot be verified
  2. Inability of the participant or LAR to understand and be willing to sign a written informed consent document.
  3. Referred families who are eligible for other CGB protocols that are specific to a hereditary cancer syndrome (e.g., Li-Fraumeni Syndrome, Familial Melanoma)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:FAMILY_BASED
  • 时间观点:OTHER

队列和干预

团体/队列
Clinical Center Cohort

includes Proband, Other carriers in family, Family Controls

Field Cohort

includes Proband, Other carriers in family, Family Controls

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Defining the natural history of familial cancers and susceptibility states over multiple generations, identifying cancer susceptibility genes, and assessing gene-environment and gene-gene interactions
大体时间:Ongoing

New cancer development or current health status

Ongoing

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sharon A Savage, M.D.、National Cancer Institute (NCI)

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年3月10日

初级完成 (估计的)

2035年12月31日

研究完成 (估计的)

2035年12月31日

研究注册日期

首次提交

2022年4月26日

首先提交符合 QC 标准的

2022年4月27日

首次发布 (实际的)

2022年4月28日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年10月27日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 10000678
  • 000678-C

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Genotype and sequence data along with clinical phenotypes will be deposited in a genomic database in accordance with current NIH Genomic Data Sharing (GDS) Policy and the NIH Human Data Sharing Policy.@@@@@@@@@@@@The following human data generated in this research will be shared for future research as follows:@@@@@@@@@@@@De-identified data in an NIH-funded or approved public repository.@@@@@@@@@@@@De-identified data in BTRIS (automatic for activities in the Clinical Center)@@@@@@@@@@@@De-identified or identified data with approved outside collaborators under appropriate agreements.@@@@@@@@@@@@The data will be shared at the time of publication or shortly after.@@@@@@@@@@@@Unlinked genomic data will be deposited in public genomic databases such as dbGaP in compliance with the NIH Genomic Data Sharing Policy.

IPD 共享时间框架

The data will be shared at the time of publication or shortly after.

IPD 共享访问标准

Section 9.10 titled Publication and Data Sharing Policy in the protocol which describes the plan for data sharing plans including human data sharing and genomic data sharing.

IPD 共享支持信息类型

  • 树液
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅